Kite Pharma Wants Fed. Circ. To Nix Juno's $1.2B Patent Win

Gilead unit Kite Pharma is asking the Federal Circuit to wipe out a $1.2 billion judgment in Juno Therapeutics Inc.'s favor in a patent case over Kite's cancer treatment Yescarta, saying...

Already a subscriber? Click here to view full article